Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Aripiprazole Sandoz (aripiprazole) — Sandoz GmbH
Authorised new aripiprazole product (Sandoz) for schizophrenia and bipolar disorder.
-
CLINICAL_TRIALS trial_result · 2026-08-21Clinical Trial Results: A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia [Phase 2]
Phase 2 trial results for CVL-231 (Emraclidine) in adults with schizophrenia have been completed with results posted. The study evaluated sa…
-
CLINICAL_TRIALS trial_result · 2026-08-21Clinical Trial Results: Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia [NA]
Clinical trial investigating low-dose levetiracetam effects on symptoms, cognition, and hippocampal activity in schizophrenia; completed wit…
-
CLINICAL_TRIALS trial_result · 2026-07-31Clinical Trial Update: Metformin Treatment on Cognitive Impairment of Schizophrenia [Phase 3]
Phase 3 clinical trial investigating metformin for cognitive impairment in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2026-07-30Clinical Trial Results: Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia [NA]
Completed clinical trial studying behavioral impact and neural correlates of network-based brain stimulation in schizophrenia and nicotine u…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-07-29EMA Authorised: Rxulti (brexpiprazole) — Otsuka Pharmaceutical Netherlands B.V.
Brexpiprazole (Rxulti) has been authorised in the EU for schizophrenia, with Otsuka Pharmaceutical Netherlands B.V. as the marketing authori…
-
CLINICAL_TRIALS trial_result · 2026-07-17Clinical Trial Results: Personalized and Scalable Cognitive Remediation Approaches [NA]
Completed clinical trial evaluating personalized and scalable cognitive remediation for schizophrenia-spectrum conditions; results posted.
-
EMA approval · 2026-07-10EMA Authorised: Olazax (olanzapine) — Glenmark Pharmaceuticals s.r.o.
Olazax, containing olanzapine, has been authorised for schizophrenia and bipolar disorder in the EU.
-
EMA approval · 2026-07-01EMA Authorised: Zypadhera (olanzapine pamoate) — CHEPLAPHARM Registration GmbH
The EMA has authorised Zypadhera (olanzapine pamoate) for schizophrenia, with CHEPLAPHARM Registration GmbH as the marketing authorisation h…
-
CLINICAL_TRIALS trial_result · 2026-06-30Clinical Trial Results: Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia [Phase 1]
Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of TV-44749 in Chinese patients with schizophrenia has completed with re…
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Results: Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia [NA]
A terminated clinical trial evaluating the use of transcranial magnetic stimulation (TMS) to understand negative symptoms in schizophrenia; …
-
CLINICAL_TRIALS trial_result · 2026-06-22Clinical Trial Results: Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia [Phase 3]
Phase 3 trial evaluating safety and effectiveness of slowly increasing dose and food effect of KarXT in participants with schizophrenia; stu…
-
CLINICAL_TRIALS trial_result · 2026-06-22Clinical Trial Results: Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents [Phase 1]
Phase 1 pharmacokinetics and tolerability study of aripiprazole in children and adolescents with schizophrenia or mania completed; results p…
-
CLINICAL_TRIALS trial_result · 2026-06-18Clinical Trial Results: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia [Phase 3]
A Phase 3 clinical trial assessing the efficacy and safety of an investigational drug for acutely psychotic schizophrenia has completed with…
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Update: Metformin Treatment on Cognitive Impairment of Schizophrenia [Phase 3]
Phase 3 clinical trial investigating metformin for cognitive impairment in schizophrenia has completed.
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Results: Multi-modal Assessment of Gamma-aminobutyric Acid (GABA) Function in Psychosis [Phase 4]
Phase 4 clinical trial assessing GABA function in psychosis across schizophrenia and bipolar disorder; results completed and posted in 2026.
-
EMA approval · 2026-06-10EMA Authorised: Byannli (previously Paliperidone Janssen-Cilag International) (paliperidone palmitate) — Janssen-Cilag International N.V.
The EMA has authorised Byannli (paliperidone palmitate) from Janssen-Cilag International for schizophrenia.
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia [Phase 3]
Extension study results for a second course of a digital therapeutic targeting experiential negative symptoms in schizophrenia, completed P…
-
EMA approval · 2026-06-03EMA Authorised: Xeplion (paliperidone palmitate) — Janssen-Cilag International N.V.
EMA authorises Xeplion (paliperidone palmitate) for schizophrenia, with Janssen-Cilag International N.V. as the MAH.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Biomarkers to Enhance Early Schizophrenia Treatment [Phase 4]
Phase 4 clinical trial investigating biomarkers to improve early treatment of schizophrenia.
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia [Phase 2]
Phase 2 clinical trial update assessing the efficacy and safety of HS-10380 in hospitalized adults with acute schizophrenia.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults [Phase 2]
A Phase 2 randomized trial is evaluating Rituximab for adults with schizophrenia spectrum and other psychotic disorders; the study is curren…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Genetic Study of Schizophrenia
A completed genetic study update investigating schizophrenia. The conditions include schizophrenia and schizoaffective disorder.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: French Validation of Schizophrenia Proneness Instrument- Child Youth [NA]
A French validation study of the Schizophrenia Proneness Instrument for Children and Youth is underway to assess its utility in identifying …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
A prospective observational study examining how sociodemographic factors, blood-based biomarkers, and psychiatric symptoms relate across sev…